RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea.
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.
Kantum Pharma, operating under the name Kantum Bio, focuses on developing therapeutics and diagnostic tests for acute kidney injury (AKI). Founded in 2016 and based in Concord, New Hampshire, the company is advancing its lead therapeutic candidate, KB-1801, aimed at preventing and treating AKI, particularly in patients undergoing cardiovascular interventions. This targeted therapy is complemented by the development of a novel diagnostic test, Uridine diphosphate glucose (UDP-G), which facilitates early diagnosis of individuals at risk for AKI. The dual approach seeks to address the critical need for effective interventions in various conditions associated with AKI, such as sepsis, polytrauma, and nephrotoxicity. By providing both therapeutic and diagnostic solutions, Kantum Bio aims to enhance patient outcomes and support critical care clinicians in preventing AKI-related complications and fatalities.
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
The company intends to use the funds to finance the development of its first product.France-based medical device company focused on innovative technologies in the cardiovascular space
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
Basking Biosciences
Seed Round in 2020
Basking Biosciences is a startup that’s developing a therapy to restore blood flow to the brain during ischemic stroke, preventing hemorrhage and long-term damage.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.
AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.
Kantum Pharma, operating under the name Kantum Bio, focuses on developing therapeutics and diagnostic tests for acute kidney injury (AKI). Founded in 2016 and based in Concord, New Hampshire, the company is advancing its lead therapeutic candidate, KB-1801, aimed at preventing and treating AKI, particularly in patients undergoing cardiovascular interventions. This targeted therapy is complemented by the development of a novel diagnostic test, Uridine diphosphate glucose (UDP-G), which facilitates early diagnosis of individuals at risk for AKI. The dual approach seeks to address the critical need for effective interventions in various conditions associated with AKI, such as sepsis, polytrauma, and nephrotoxicity. By providing both therapeutic and diagnostic solutions, Kantum Bio aims to enhance patient outcomes and support critical care clinicians in preventing AKI-related complications and fatalities.
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other serious age-related conditions. The company specializes in precision pharmaceuticals, creating innovative genetic treatments that are selectively targeted to specific tissues and cells. HAYA Therapeutics employs a discovery engine that identifies tissue- and cell-specific drivers of fibrosis and other disease processes by leveraging non-coding RNAs in the human genome. Through its biopharmaceutical therapies, HAYA Therapeutics seeks to block myocardial fibrosis, offering potential new options for the management of heart failure and related disorders.
Epirium Bio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases and metabolic syndrome. Established in 2008, the company has gained insights into mitochondrial biogenesis and function, leading to the discovery of a novel pharmacological approach for treating conditions associated with mitochondrial deficits. Epirium Bio has developed an intellectual property-protected platform of small molecules that represent a new class of therapeutics aimed at stimulating mitochondrial biogenesis and function. Their lead clinical candidate has demonstrated the ability to trigger mitochondrial biogenesis in early human studies and is being developed for various therapeutic areas, with an initial focus on rare diseases, neuromuscular, and neurodegenerative disorders. This innovative approach seeks to provide new treatment options for patients suffering from conditions such as muscular dystrophy.
CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.
Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.
AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.
Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, founded in 2011. The company specializes in developing innovative cardiac monitoring systems for patients with congestive heart failure. Its flagship product, the V-LAP, is a pioneering in-heart microcomputer that monitors left atrial pressure (LAP), a key indicator for heart failure deterioration. This digital, wireless, and battery-less sensory implant offers daily push-button readings, allowing for timely and effective interventions. Vectorious is actively conducting clinical studies in Europe, including countries like Italy, Germany, and the UK, to obtain regulatory approval. The company aims to enhance the quality of life and life expectancy for heart failure patients through its advanced monitoring technology.
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the development of surgical anastomotic technology aimed at treating obesity and type 2 diabetes. Founded in 2012, the company focuses on creating innovative solutions that facilitate less invasive surgical procedures, thereby expanding the range of available medical interventions. G.I. Windows is dedicated to improving healthcare outcomes by balancing the needs of patients with the overall efficiency of the healthcare system. Through its groundbreaking technology, the company aims to establish a new category in healthcare that not only enhances procedural effectiveness but also reduces costs associated with surgical treatments.
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on developing peptide drugs aimed at treating dietary-related metabolic diseases, specifically obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics specializes in creating peptide-based GIP receptor antagonists that help monitor and manage these conditions by effectively reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to provide therapeutic solutions that address the growing challenges associated with metabolic disorders.
Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications.
Mellitus, LLC is a biotechnology company specializing in the development of in vitro diagnostic tests aimed at improving the detection and monitoring of diabetes. The company focuses on a novel test for measuring Glycated CD59 (GCD59), which serves as a biomarker with significant clinical potential for screening, diagnosing, and monitoring diabetes, particularly gestational diabetes mellitus. This test also plays a role in assessing the risk of complications and can be utilized in pharmaceutical clinical trials. Founded in 2011 and based in Boston, Massachusetts, Mellitus is dedicated to enhancing healthcare professionals' ability to identify diabetes-related risks swiftly and effectively.
CellAegis Devices Inc. is a Toronto-based company that develops, manufactures, and commercializes medical devices aimed at enhancing cardiovascular care. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner, providing critical therapy to minimize heart damage during heart attacks and various cardiovascular procedures. Additionally, the company offers CRICtrac, a mobile application that enables clinicians to administer self-delivered chronic RIC therapy to patients at home. CellAegis Devices caters to a wide range of settings, including hospitals, ambulances, and home care, and serves markets in Canada, Europe, and the United States.
Nido Surgical, Inc. is a medical device company founded in 2014 and located in Needham, Massachusetts. The company focuses on developing innovative surgical instruments for heart surgery, specifically through its flagship product, SEPIA. This Epicardial Ablation Solution is designed to address cardiac arrhythmias and facilitates video-endoscopic trans-cardiac surgical repairs within the beating heart. By enabling access through small incisions in the chest and heart wall, Nido's technology allows physicians to perform minimally invasive procedures without the need for cardiopulmonary bypass, enhancing surgical efficiency and patient recovery.
Aeromics, LLC, a preclinical company, develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity; and blocks edema in models of cardiac ischemia and transplant. The company was founded in 2006 and is based in Cleveland, Ohio. Aeromics, LLC operates as a subsidiary of Case Western Reserve University.
The company intends to use the funds to finance the development of its first product.France-based medical device company focused on innovative technologies in the cardiovascular space
Gila Therapeutics, Inc. is a privately-held company based in Minneapolis, Minnesota, founded in January 2014 by Dr. Andres Acosta and Dr. Sergei Zolotukhin. The company focuses on developing innovative therapies for obesity, utilizing the discoveries made by its founders to explore a novel treatment pathway. Its lead product, GT-002, is a PYY3-36 agonist designed to promote a sense of fullness, thereby reducing caloric intake and facilitating weight loss. Through its research and development efforts, Gila Therapeutics aims to address the growing obesity epidemic with effective therapeutic options.
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Pulmokine is a privately held biopharmaceutical company dedicated to developing therapies for challenging pulmonary diseases, specifically focusing on conditions such as pulmonary arterial hypertension (PAH), pulmonary arterial fibrosis, interstitial lung disease, sarcoidosis, and lung cancer. Leveraging innovative kinase inhibitor technology, Pulmokine aims to create effective treatments that address the needs of patients suffering from these serious lung conditions. Through its targeted approach, the company seeks to improve patient outcomes and expand the options available for managing difficult-to-treat pulmonary ailments.
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.
Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, specializing in the development of medical treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia. Founded in 2011, the company focuses on creating SK channel inhibitors, which are designed to be safe and tolerable options for patients. These drugs work by inhibiting specific ion channels in heart cells that are crucial for generating the electrical signals that regulate the heart's rhythm. Acesion Pharma aims to provide effective chronic treatments that prevent the recurrence of AF and help maintain a normal heart rhythm.
Ischemia Care, LLC is a molecular diagnostic company based in Oxford, Ohio, specializing in blood tests designed to aid in the diagnosis of ischemic strokes and transient ischemic attacks. By utilizing RNA expression analysis, Ischemia Care offers several diagnostic products including ISCDx, which helps determine the cause of a stroke, and various tests that can be performed in hospital labs or outsourced to CLIA-certified laboratories. The company's tests serve as clinical workflow tools that empower physicians with critical information to stratify patients by stroke cause, enabling them to select appropriate treatment pathways and ultimately improve patient outcomes while reducing hospital costs. Established in 2009, Ischemia Care emphasizes the importance of timely diagnosis and intervention in acute medical situations.
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.
InfoBionic, Inc. is a healthcare technology company based in Massachusetts, founded in 2011. It specializes in remote patient monitoring through its MoMe™ platform, which is a cloud-based service designed to enhance the efficiency of cardiac diagnostic services. The MoMe System focuses on cardiac arrhythmia detection, allowing healthcare providers to monitor patients' heart health continuously by streaming electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This technology aims to improve clinical efficiency and patient care by providing physicians with anytime, anywhere access to critical patient data, ultimately facilitating better detection and treatment of cardiac complications.
ZZ Biotech, LLC develops biological treatments for the aging and damaged brain, including those affected by stroke and other neurodegenerative disorders. It provides 3K3A-APC, a genetically engineered variant of the naturally occurring activated protein-C (APC) that regulates blood clotting and inflammation. The company was founded in 2006 and is based in Houston, Texas.
Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company based in New York that specializes in developing small molecule drugs aimed at treating acute central nervous system disorders. Founded in 2004, the company focuses on addressing conditions such as stroke, traumatic brain injury, spinal cord injury, organ ischemia, and complications arising from CNS surgery. One of its key products, RP-1127, is an intravenous formulation of glyburide, which acts as an inhibitor of NCCa-ATP channels by antagonizing the type-1 sulfonylurea receptor. The company's innovative approach targets critical aspects of central nervous system injuries, highlighting its commitment to advancing treatment options in this vital area of healthcare.
Apama Medical, Inc. manufactures catheter ablation technology devices for the treatment of atrial fibrillation (AF). Its product, include Apama radiofrequency (RF) balloon catheter system, a single-shot, multi-electrode technology which is designed to combine the benefits of both RF point-by-point and balloon-based ablation approaches. Its technology incorporates built-in digital cameras with LED lights and sensing electrodes on the balloon which allow for real-time visualization and assessment of catheter electrode contact. The company was incorporated in 2009 and is based in Campbell, California. As of October 10, 2017, Apama Medical, Inc. operates as a subsidiary of Boston Scientific Corporation.
BioKier, Inc. is an early-stage pharmaceutical company based in Chapel Hill, North Carolina, focused on developing medications for diabetes and related disorders. The company specializes in oral pills designed to treat type 2 diabetes, metabolic syndrome, and obesity. BioKier’s lead product features L-glutamine, a natural compound commonly found in food. Established in 2008, BioKier aims to address significant health challenges associated with these conditions through innovative therapeutic solutions.
Zumbro Discovery, Inc. is developing a novel natriuretic peptide, MANP, for the treatment of resistant hypertension for which there is an unmet medical need for a syndrome which increases risk for heart failure, myocardial infarction, stroke and kidney disease. MANP was discovered at the Mayo Clinic and is soon entering first in human studies.
DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute tissue damaging inflammation in myocardial infarction, burns, vascular injury, and reperfusion. It develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune Therapeutics, Inc. was formerly known as Natural Antibodies, Inc. and changed its name to DecImmune Therapeutics, Inc. in September 2004. The company was incorporated in 2001 and is based in Cambridge, Massachusetts.
Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and oncology. Using two proprietary technologies, Laurantis is developing first-in-class products for commercially and medically significant niche indications in these areas. Laurantis was formed in December 2010 through a merger of the Finnish drug development companies Oy Lx Therapies Ltd and BioCis Pharma Oy.
Herantis Pharma Oyj is a drug development company based in Espoo, Finland, established in 2008. The company focuses on regenerative medicine and aims to address unmet clinical needs through its innovative therapies. Its product pipeline includes CDNF, currently undergoing Phase I-II clinical trials for the treatment of Parkinson’s disease, and is also in preclinical development for amyotrophic lateral sclerosis. Additionally, Herantis Pharma is advancing Lymfactin, which is in Phase II clinical trials aimed at treating lymphedema associated with breast cancer. Through its research and development efforts, the company seeks to provide effective solutions for serious health conditions.
InfoBionic, Inc. is a healthcare technology company based in Massachusetts, founded in 2011. It specializes in remote patient monitoring through its MoMe™ platform, which is a cloud-based service designed to enhance the efficiency of cardiac diagnostic services. The MoMe System focuses on cardiac arrhythmia detection, allowing healthcare providers to monitor patients' heart health continuously by streaming electrocardiogram, respiration, and motion data to the cloud for real-time analysis. This technology aims to improve clinical efficiency and patient care by providing physicians with anytime, anywhere access to critical patient data, ultimately facilitating better detection and treatment of cardiac complications.
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.
VGS develops innovative solutions to improve the outcome of bypass surgery and patients’ quality of life. VEST, the company’s leading product, is designed for use in Coronary Artery Bypass Grafting, to mitigate disease progression in venous bypass grafts and improve their long term performance.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Apama Medical, Inc. manufactures catheter ablation technology devices for the treatment of atrial fibrillation (AF). Its product, include Apama radiofrequency (RF) balloon catheter system, a single-shot, multi-electrode technology which is designed to combine the benefits of both RF point-by-point and balloon-based ablation approaches. Its technology incorporates built-in digital cameras with LED lights and sensing electrodes on the balloon which allow for real-time visualization and assessment of catheter electrode contact. The company was incorporated in 2009 and is based in Campbell, California. As of October 10, 2017, Apama Medical, Inc. operates as a subsidiary of Boston Scientific Corporation.
Provasculon is a biotechnology company focused on developing novel therapeutic proteins aimed at healing organs damaged by ischemia. Founded based on the discoveries of Richard Lee, MD, and Vincent Segers, MD, both affiliated with Brigham and Women's Hospital, Provasculon specializes in innovative applications of Stromal Cell-Derived Factor-1 (SDF-1). The company's lead therapeutic protein shows promise in restoring the function of hearts severely affected by ischemic conditions, potentially bringing them back to near normal performance. Through its research and development efforts, Provasculon seeks to address critical medical needs in the treatment of ischemic organ damage.
Aggamin Pharmaceuticals, LLC is a biotechnology company established in 2010 and located in New York. The company focuses on developing and commercializing innovative therapies for vascular diseases, with a primary emphasis on preeclampsia, a serious condition affecting about 5% of pregnancies and imposing a significant financial burden on the U.S. healthcare system. Aggamin's lead product is an extracorporeal device designed to reduce harmful circulating proteins associated with preeclampsia, aiming to improve both maternal and fetal health. By restoring the angiogenic balance disrupted in this condition, the company's objective is to provide a safe, first-in-class treatment that alleviates maternal symptoms, extends pregnancy duration, and enhances outcomes for both mothers and newborns.
Coridea is an idea generator, technology incubator, and consulting firm focused on the development of medical devices in the cardio-renal and cardio-pulmonary fields. Established in 2003, the company has successfully launched six startups, including notable firms like Ardian and CHF Solutions. The acquisition of Ardian by Medtronic, valued at $800 million, stands as a significant milestone in the medical device sector. Coridea has secured 65 U.S. patents, which have been licensed to various companies, and has raised over $150 million in venture capital financing. The company is recognized for its innovation, exemplified by the award-winning Symplicity® Catheter System™, which garnered the Edison Award in 2011. Coridea aims to provide physiologically-based solutions for complex medical challenges, impacting the lives of patients with cardiac, pulmonary, renal, and neuro conditions.
NuPulse is a medical device company based in Raleigh, North Carolina, that specializes in developing technology for the treatment of advanced chronic heart failure. Established in 2010, the company focuses on creating minimally invasive solutions, notably its iVAS device, which employs ambulatory counterpulsation techniques. This device offers an alternative to traditional medical therapies, particularly for patients who do not respond to current treatments. NuPulse's founders bring a wealth of experience from clinical, engineering, and life sciences backgrounds, positioning the company to significantly impact heart failure management. The iVAS device is currently undergoing clinical trials to evaluate its effectiveness for patients with symptoms classified as New York Heart Association (NYHA) functional classes III and IV. By providing patients with a less invasive treatment option, NuPulse aims to improve their quality of life and facilitate a return to daily activities.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Capricor Therapeutics is a clinical-stage biotechnology company headquartered in Beverly Hills, California, specializing in the discovery, development, and commercialization of biological therapies for the treatment of diseases, particularly Duchenne muscular dystrophy (DMD) and other rare disorders. The company's lead product candidate, CAP-1002, is an allogeneic cell therapy currently in phase II clinical trials aimed at treating late-stage DMD. Additionally, Capricor has explored CAP-1002 for other cardiac conditions, including heart failure and post-myocardial infarction complications. The company is also developing CAP-2003, which is in pre-clinical development for inflammatory conditions, alongside other innovative therapeutic approaches, including exosome-based treatments and vaccines. Founded in 2005, Capricor Therapeutics is committed to addressing unmet medical needs through its advanced therapeutic programs.
CellAegis Devices Inc. is a Toronto-based company that develops, manufactures, and commercializes medical devices aimed at enhancing cardiovascular care. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner, providing critical therapy to minimize heart damage during heart attacks and various cardiovascular procedures. Additionally, the company offers CRICtrac, a mobile application that enables clinicians to administer self-delivered chronic RIC therapy to patients at home. CellAegis Devices caters to a wide range of settings, including hospitals, ambulances, and home care, and serves markets in Canada, Europe, and the United States.
Intravascular Imaging focuses on developing advanced techniques for detecting and assessing atherosclerotic plaques in human arteries. Established through a collaboration between Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, the company aims to enhance cardiovascular imaging technologies. Its offerings include prototype devices, software, and systems designed to improve early detection of coronary artery disease and evaluate therapeutic viability after interventions. By providing a comprehensive catheter-based approach, Intravascular Imaging enables healthcare providers to identify high-risk plaques more effectively, thereby reducing hospital readmissions following percutaneous coronary interventions. This commitment to advancing biological imaging modalities underscores the company's dedication to improving patient outcomes in cardiovascular health.
Allosteros
Seed Round in 2010
Allosteros Therapeutics Inc. engages in discovery and development of breakthrough small molecule drugs that target allosteric sites on key proteins in disease pathways. Allosteros Therapeutics Inc. was incorporated in 2009 and is based in Palo Alto, California.
VentriNova is a regenerative medicine company dedicated to reversing cardiac damage through the activation of intrinsic repair pathways that generate new heart muscle cells. The company focuses on developing clinical treatments and gene therapies aimed at regenerating heart tissue. Its first-generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue, promoting the proliferation of cardiac muscle cells. This innovative approach enables healthcare providers to offer potential cures for patients suffering from heart failure.
MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.
CardiAQ Valve Technologies (CVT), a privately held company, is developing innovative approaches to heart valve replacement and is initially focused on transcatheter mitral valve implantation (TMVI).